MPCCC-Monash BDI Cancer Discovery Seminar Series: Assoc Prof Misty Jenkins AO
July 18 @ 12:00 pm - 1:00 pm
Developing Novel CAR T Cells For Brain Cancer
VENUE: CL_15 Innovation Walk, Room G19, Meeting (Bldg 75)
NHMRC fellow, lab head, Immunology Division,
Walter and Eliza Hall Institute for Medical Research
Chimeric Antigen Receptors (CARs) are synthetic receptors composed of an antigen-binding domain fused to transmembrane and signalling domains. CARs transduced into T cells can then be directed the T cells’ endogenous recognition and killing machinery to eliminate cancer cells.
Therefore, chimeric antigen receptor (CAR) T cell therapy represents a ground-breaking approach in cancer treatment, modifying a patient’s T cells to express a CAR receptor that recognizes specific antigens on the tumour cell surface.
ABOUT THE PRESENTER
Misty Rayna Jenkinsis an Australian scientist known for her research into lymphocytes and cancer treatment.
Jenkins leads an Immunology Laboratory at the Walter and Eliza Hall Institute of Medical Research where she researches brain cancer and aims to establish a world-leading immunotherapy lab specialising in researching the possibilities of new treatments for both adult and paediatric brain cancer.